aTYR PHARMA INC 8K

aTyr Pharma announced a major restructuring and 60% workforce reduction, C‑suite changes, and a strategic focus on its efzofitimod ILD program alongside reporting Q2 2026 results and outlining Phase 2/3 clinical and cash runway plans.

aTyr Pharma, Inc. reported its second quarter 2026 financial results and announced a major program prioritization and corporate restructuring to conserve capital and focus on advancing its lead drug candidate efzofitimod for interstitial lung diseases, including pulmonary sarcoidosis and SSc‑ILD. The restructuring includes a workforce reduction of approximately 60%, the planned departure of CFO Jill Broadfoot and General Counsel Nancy Denyes on September 30, 2026 (with both transitioning to consulting roles), and the promotion of Vice President of Finance Brandon Yaras to CFO effective October 1, 2026. The company has submitted a protocol to the FDA (in June 2026) for a planned global Phase 3 study of efzofitimod in pulmonary sarcoidosis and expects FDA feedback by the end of August 2026, while enrollment has been completed in the Phase 2 EFZO‑CONNECT study in SSc‑ILD with topline data expected in the first quarter of 2027. aTyr ended the quarter with $58.9 million in cash, cash equivalents, restricted cash and investments, expects the restructuring and additional cost-saving measures to reduce annualized operating expenses by about $13 million beginning in Q4 2026, and believes its current cash will fund operations into late 2028, though it will need additional capital to fully fund the planned Phase 3 efzofitimod program.

Filing Facts

CIK

1339970

Ticker

-

Form

8K

Source Type

sec

Accession

0001339970-26-000051

Alert Tier

7